| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Corinne A Betts, Graham McClorey, Richard Healicon, Suzan M Hammond, Raquel Manzano, Sofia Muses, Vicky Ball, Caroline Godfrey, Thomas M Merritt, Tirsa van Westering, Liz O'Donovan, Kim E Wells, Michael J Gait, Dominic J Wells, Damian Tyler, Matthew J Woo. Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment. Human molecular genetics. vol 28. issue 3. 2019-07-15. PMID:30281092. |
duchenne muscular dystrophy (dmd) is caused by loss of dystrophin protein, leading to progressive muscle weakness and premature death due to respiratory and/or cardiac complications. |
2019-07-15 |
2023-08-13 |
mouse |
| David R Weber, Stasia Hadjiyannakis, Hugh J McMillan, Garey Noritz, Leanne M War. Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. vol 142. issue Suppl 2. 2019-06-03. PMID:30275248. |
duchenne muscular dystrophy (dmd) is associated with an increased risk of endocrine complications due to the effects of prolonged glucocorticoid therapy as well as progressive muscle weakness. |
2019-06-03 |
2023-08-13 |
Not clear |
| Mutsuki Kuraoka, Yuko Nitahara-Kasahara, Hisateru Tachimori, Naohiro Kato, Hiroyuki Shibasaki, Akihiko Shin, Yoshitsugu Aoki, En Kimura, Shin'ichi Taked. Accelerometric outcomes of motor function related to clinical evaluations and muscle involvement in dystrophic dogs. PloS one. vol 13. issue 12. 2019-05-30. PMID:30533017. |
patients with dmd reveal progressive muscle weakness leading to ambulatory dysfunction. |
2019-05-30 |
2023-08-13 |
human |
| Jennifer G Andrews, Kristin Conway, Christina Westfield, Christina Trout, F John Meaney, Katherine Mathews, Emma Ciafaloni, Christopher Cunniff, Deborah J Fox, Dennis Matthews, Shree Pandy. Implementation of Duchenne Muscular Dystrophy Care Considerations. Pediatrics. vol 142. issue 1. 2019-04-29. PMID:29925575. |
duchenne muscular dystrophy (dmd) is an x-linked disorder characterized by progressive muscle weakness and multisystem involvement. |
2019-04-29 |
2023-08-13 |
Not clear |
| Jennifer G Andrews, Molly M Lamb, Kristin Conway, Natalie Street, Christina Westfield, Emma Ciafaloni, Dennis Matthews, Christopher Cunniff, Shree Pandya, Deborah J Fo. Diagnostic Accuracy of Phenotype Classification in Duchenne and Becker Muscular Dystrophy Using Medical Record Data1. Journal of neuromuscular diseases. vol 5. issue 4. 2019-01-31. PMID:30320597. |
dystrophinopathies are caused by mutations in dmd resulting in progressive muscle weakness. |
2019-01-31 |
2023-08-13 |
Not clear |
| Marianna Laviola, Rita Priori, Maria Grazia D'Angelo, Andrea Alivert. Assessment of diaphragmatic thickness by ultrasonography in Duchenne muscular dystrophy (DMD) patients. PloS one. vol 13. issue 7. 2019-01-30. PMID:30048455. |
in duchenne muscular dystrophy (dmd) the assessment of diaphragmatic function is crucial because respiratory muscle weakness can cause respiratory failure. |
2019-01-30 |
2023-08-13 |
Not clear |
| Sabrina Poonja, Alyssa Power, Jean K Mah, Nowell M Fine, Steven C Greenwa. Current Cardiac Imaging Approaches in Duchenne Muscular Dystrophy. Journal of clinical neuromuscular disease. vol 20. issue 2. 2019-01-29. PMID:30439754. |
duchenne muscular dystrophy (dmd) is an x-linked neuromuscular condition caused by mutations in the dystrophin gene leading to skeletal muscle weakness and dilated cardiomyopathy. |
2019-01-29 |
2023-08-13 |
Not clear |
| Wen-Chen Liang, Chen-Hua Wang, Po-Ching Chou, Wan-Zi Chen, Yuh-Jyh Jon. The natural history of the patients with Duchenne muscular dystrophy in Taiwan: A medical center experience. Pediatrics and neonatology. vol 59. issue 2. 2019-01-07. PMID:28903883. |
in addition to progressive proximal muscle weakness, respiratory, orthopedic, and gastrointestinal complications are often observed in dmd. |
2019-01-07 |
2023-08-13 |
Not clear |
| Kota Utsumi, Kouji Takano, Yoji Okahara, Tetsuo Komori, Osamu Onodera, Kenji Kansak. Operation of a P300-based brain-computer interface in patients with Duchenne muscular dystrophy. Scientific reports. vol 8. issue 1. 2018-12-11. PMID:29379140. |
this technology has been tested in paralysed patients, such as those with cervical spinal cord injuries or amyotrophic lateral sclerosis, but it has not been tested systematically in duchenne muscular dystrophy (dmd), which is a severe type of muscular dystrophy due to the loss of dystrophin and is often accompanied by progressive muscle weakness and wasting. |
2018-12-11 |
2023-08-13 |
Not clear |
| Marije Goudriaan, Marleen Van den Hauwe, Cristina Simon-Martinez, Catherine Huenaerts, Guy Molenaers, Nathalie Goemans, Kaat Desloover. Gait deviations in Duchenne muscular dystrophy-Part 2. Statistical non-parametric mapping to analyze gait deviations in children with Duchenne muscular dystrophy. Gait & posture. vol 63. 2018-10-24. PMID:29751322. |
also, while muscle weakness is often suggested to be the main cause for the altered gait pattern in dmd, this was never verified. |
2018-10-24 |
2023-08-13 |
Not clear |
| Arash Salmaninejad, Saeed Farajzadeh Valilou, Hadi Bayat, Nader Ebadi, Abdolreza Daraei, Meysam Yousefi, Abolfazl Nesaei, Majid Mojarra. Duchenne muscular dystrophy: an updated review of common available therapies. The International journal of neuroscience. vol 128. issue 9. 2018-10-11. PMID:29351004. |
dmd leads to progressive muscle weakness, degeneration, and wasting; finally, follows with the premature demise in affected individuals due to respiratory and/or cardiac failure typically by age of 30. |
2018-10-11 |
2023-08-13 |
Not clear |
| Michael St Andre, Mark Johnson, Prashant N Bansal, Jeremy Wellen, Andrew Robertson, Alan Opsahl, Peter M Burch, Peter Bialek, Carl Morris, Jane Owen. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skeletal muscle. vol 7. issue 1. 2018-09-24. PMID:29121992. |
therefore, myostatin blockade via a specific antibody could ameliorate the muscle weakness in dmd patients by increasing skeletal muscle mass and function, thereby reducing patients' functional decline. |
2018-09-24 |
2023-08-13 |
mouse |
| Antonio Filareto, Katie Maguire-Nguyen, Qiang Gan, Garazi Aldanondo, Léo Machado, Jeffrey S Chamberlain, Thomas A Rand. Monitoring disease activity noninvasively in the Proceedings of the National Academy of Sciences of the United States of America. vol 115. issue 30. 2018-09-17. PMID:29987034. |
dmd is characterized by progressive loss of muscle fibers, muscle weakness, and eventually loss of ambulation and premature death. |
2018-09-17 |
2023-08-13 |
Not clear |
| Talita Dias da Silva, Thais Massetti, Tânia Brusque Crocetta, Carlos Bandeira de Mello Monteiro, Alex Carll, Luiz Carlos Marques Vanderlei, Carlie Arbaugh, Fernando Rocha Oliveira, Luiz Carlos de Abreu, Celso Ferreira Filho, John Godleski, Celso Ferreir. Heart Rate Variability and Cardiopulmonary Dysfunction in Patients with Duchenne Muscular Dystrophy: A Systematic Review. Pediatric cardiology. vol 39. issue 5. 2018-09-12. PMID:29696428. |
duchenne muscular dystrophy (dmd) is a genetic recessive disorder with progressive muscle weakness. |
2018-09-12 |
2023-08-13 |
Not clear |
| Feng Liang, Christian Giordano, Dong Shang, Qian Li, Basil J Petro. The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmdmdx-4Cv) mice. PloS one. vol 13. issue 3. 2018-07-09. PMID:29561896. |
duchenne muscular dystrophy (dmd) is characterized by progressive muscle weakness which is ultimately fatal, most often due to involvement of the diaphragm. |
2018-07-09 |
2023-08-13 |
mouse |
| Stephen J P Pratt, Shama R Iyer, Sameer B Shah, Richard M Loverin. Imaging Analysis of the Neuromuscular Junction in Dystrophic Muscle. Methods in molecular biology (Clifton, N.J.). vol 1687. 2018-06-05. PMID:29067656. |
duchenne muscular dystrophy (dmd), caused by the absence of the protein dystrophin, is characterized as a neuromuscular disease in which muscle weakness, increased susceptibility to muscle injury, and inadequate repair appear to underlie the pathology. |
2018-06-05 |
2023-08-13 |
mouse |
| Wilson Savino, Fernanda Pinto-Mariz, Vincent Moul. Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy. Methods in molecular biology (Clifton, N.J.). vol 1687. 2018-06-05. PMID:29067667. |
duchenne muscular dystrophy (dmd) affects 1:3500-1:5000 male births, and is caused by x-linked mutations in the dystrophin gene, manifested by progressive muscle weakness and wasting due to the absence of dystrophin protein, leading to degeneration of skeletal muscle. |
2018-06-05 |
2023-08-13 |
Not clear |
| Henri Meric, Line Falaize, Didier Pradon, Matthieu Lacombe, Michel Petitjean, David Orlikowski, Hélène Prigent, Frédéric Lofas. Short-term effect of volume recruitment-derecruitment manoeuvre on chest-wall motion in Duchenne muscular dystrophy. Chronic respiratory disease. vol 14. issue 2. 2018-05-11. PMID:27923984. |
because progressive respiratory muscle weakness leads to decreased chest-wall motion with eventual ribcage stiffening, the purpose was to compare vital capacity (vc) and contributions of chest-wall compartments before and after volume recruitment-derecruitment manoeuvres (vrdm) in duchenne muscular dystrophy (dmd). |
2018-05-11 |
2023-08-13 |
Not clear |
| Cuixia Tian, Brenda L Wong, Lindsey Hornung, Jane C Khoury, Lauren Miller, Jean Bange, Irina Rybalsky, Meilan M Rutte. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy. Neuromuscular disorders : NMD. vol 26. issue 11. 2018-01-25. PMID:27614576. |
osteoporosis is a major problem in boys with duchenne muscular dystrophy (dmd), attributable to muscle weakness and glucocorticoid therapy. |
2018-01-25 |
2023-08-13 |
Not clear |
| Kent Heberer, Eileen Fowler, Loretta Staudt, Susan Sienko, Cathleen E Buckon, Anita Bagley, Mitell Sison-Williamson, Craig M McDonald, Michael D Sussma. Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy. Gait & posture. vol 48. 2017-12-19. PMID:27267770. |
duchenne muscular dystrophy (dmd) is an x-linked genetic neuromuscular disorder characterized by progressive proximal to distal muscle weakness. |
2017-12-19 |
2023-08-13 |
Not clear |